Prediction of drug class and adverse side effects based on induced gene expression profiles - a feasability study

[1]  David J. Hand,et al.  Classifier Technology and the Illusion of Progress , 2006, math/0606441.

[2]  Christopher P Austin,et al.  The completed human genome: implications for chemical biology. , 2003, Current opinion in chemical biology.

[3]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[4]  A. Barsky,et al.  Nonspecific medication side effects and the nocebo phenomenon. , 2002, JAMA.

[5]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[6]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[7]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[8]  Gert R. G. Lanckriet,et al.  Classification of a large microarray data set: algorithm comparison and analysis of drug signatures. , 2005, Genome research.

[9]  J. Castle,et al.  An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.

[10]  Faïçal Larachi,et al.  Feature Selection Methods for Multiphase Reactors Data Classification , 2005 .

[11]  Michal Vieth,et al.  Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.

[12]  B. Efron.  Estimating the Error Rate of a Prediction Rule: Improvement on Cross-Validation , 1983 .

[13]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[14]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[15]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[16]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[17]  Trevor Hastie,et al.  Model Assessment and Selection , 2009 .

[18]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[19]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[20]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[21]  David S. Roos,et al.  TDR Targets: a chemogenomics resource for neglected diseases , 2011, Nucleic Acids Res..

[22]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[23]  Daniel C. Liebler,et al.  Elucidating mechanisms of drug-induced toxicity , 2005, Nature Reviews Drug Discovery.

[24]  Sung-Bae Cho,et al.  A probabilistic multi-class strategy of one-vs.-rest support vector machines for cancer classification , 2008, Neurocomputing.

[25]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[26]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[27]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[29]  Doheon Lee,et al.  Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.

[30]  Bernard F. Buxton,et al.  Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..

[31]  A. Orth,et al.  Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Robert Gentleman,et al.  Distance Measures in DNA Microarray Data Analysis , 2005 .

[33]  Randall T Peterson,et al.  Chemical biology and the limits of reductionism. , 2008, Nature chemical biology.

[34]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[35]  Sorin Draghici,et al.  Machine Learning and Its Applications to Biology , 2007, PLoS Comput. Biol..

[36]  Vincent J. Carey.  Machine Learning Concepts and Tools for Statistical Genomics , 2005 .

[37]  Jae Yong Cho,et al.  Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer , 2011, PloS one.

[38]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[39]  J. Bajorath.  Computational analysis of ligand relationships within target families. , 2008, Current opinion in chemical biology.

[40]  Pedro Larrañaga,et al.  A review of feature selection techniques in bioinformatics , 2007, Bioinform..

[41]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.